ID: h-var-135da2778f
Hypothesis

ω-3 Docosahexaenoic Acid (DHA) Metabolism via 15-Lipoxygenase to Generate Specialized Pro-Resolving Mediators Against Neuroinflammation in Alzheimer's Disease

This hypothesis proposes that 15-lipoxygenase (15-LOX) enzymatically converts docosahexaenoic acid (DHA) into specialized pro-resolving mediators (SPMs), specifically resolvin D1 (RvD1) and protectin D1 (PD1), to combat neuroinflammation.
🧬 ALOX15/15-LOX🩺 lipidomics🎯 Composite 38%💱 $0.48▲21.5%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 5 support 3 oppose
✓ All Quality Gates Passed
Mechanistic 0.80 (15%) Evidence 0.34 (15%) Novelty 0.00 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.80 (10%) Safety 0.70 (8%) Competition 0.55 (6%) Data Avail. 0.75 (5%) Reproducible 0.75 (5%) KG Connect 0.50 (8%) 0.380 composite

🧪 Overview

This hypothesis proposes that 15-lipoxygenase (15-LOX) enzymatically converts docosahexaenoic acid (DHA) into specialized pro-resolving mediators (SPMs), specifically resolvin D1 (RvD1) and protectin D1 (PD1), to combat neuroinflammation in Alzheimer's disease rather than focusing on membrane rigidification. The mechanism centers on 15-LOX's ability to perform stereoselective oxygenation of DHA at the 17S position, initiating a biosynthetic cascade that produces these potent anti-inflammatory and pro-resolution lipid mediators. Unlike the parent hypothesis targeting membrane protection, this variant addresses the inflammatory component of Alzheimer's pathogenesis through active resolution of neuroinflammation. RvD1 and PD1 function by binding to specific G-protein coupled receptors (GPR32, ALX/FPR2) on microglia and astrocytes, triggering signaling cascades that promote efferocytosis of apoptotic neurons, reduce pro-inflammatory cytokine production (TNF-α, IL-1β), and enhance neuroprotective factor release (BDNF, NGF).

...

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["DHA Substrate Pool<br/>Membrane Omega-3 Lipids"]
    B["CYP2J2 Epoxygenase<br/>DHA-to-Epoxide Conversion"]
    C["Epoxy-DHA Mediators<br/>Anti-inflammatory Lipid Signals"]
    D["sEH Inhibition<br/>Epoxide Lifetime Prolonged"]
    E["Synaptic Membrane Fluidity<br/>A-beta-Induced Rigidification Blocked"]
    F["Excitatory Signaling Stability<br/>Receptor Mobility Preserved"]
    G["Synaptic Protection<br/>Reduced A-beta Toxicity"]
    A --> B
    B --> C
    D --> C
    C --> E
    E --> F
    F --> G
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style D fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
    style G fill:#1b5e20,stroke:#81c784,color:#81c784

⚖️ Evidence

⚖️ Evidence Matrix5 supports3 contradicts
Supports
CYP2J2-derived epoxides protect against Aβ-induced membrane rigidity in planar lipid bilayer experiments
Supports
DHA supplementation in 5xFAD mice reduces Aβ burden and improves synaptic plasticity markers
Supports
Soluble Aβ oligomers increase membrane cholesterol by 40% and raft domain size in cortical neurons
Supports
EC-5026 (sEH-397) Phase I completed, FDA IND cleared 2019 for pain indication
EicOsis/UC Davis clinical registry
Supports
GSK225629 Phase I completed for COPD/pain with CNS penetration demonstrated
GlaxoSmithKline clinical registry
Contradicts
Epoxides are rapidly metabolized by soluble epoxide hydrolase (sEH), with half-lives of 2-4 hours in plasma
Contradicts
The membrane fluidity model was tested in artificial planar bilayers, not neuronal membranes
Skeptic critique
Contradicts
DHA supplementation activates multiple pathways (resolvins, protectins, maresins)—benefits cannot be attributed specifically to CYP2J2 epoxides
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — ALOX15

No curated PDB or AlphaFold mapping for ALOX15 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for ALOX15/15-LOX from GTEx v10.

Nucleus accumbens basal ganglia1.1 Caudate basal ganglia0.8 Putamen basal ganglia0.5 Cortex0.3 Hypothalamus0.3 Frontal Cortex BA90.3 Hippocampus0.2 Anterior cingulate cortex BA240.1median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for ALOX15 →

No DepMap CRISPR Chronos data found for ALOX15.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.3%
Volatility
Low
0.0200
Events (7d)
2
Price History
▲21.5%

💾 Resource Usage

LLM Tokens
38,938
$0.1168
Total Cost
$0.1168
Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
sourcev1_phase_c_backfill
origin_typegap_debate
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.